Prothena Corporation plc (PRTA) Income Statement Analysis

See more : Belararox Limited (BRX.AX) Income Statement Analysis – Financial Results

Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Prothena Corporation plc (PRTA)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.prothena.com

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	91.37M	53.91M	200.58M	853.00K	814.00K	955.00K	27.52M	1.06M	1.61M	50.85M	676.00K	2.66M	507.00K	1.24M
Cost of Revenue	220.57M	6.74M	82.28M	74.88M	50.84M	101.18M	134.55M	119.53M	58.44M	38.45M	26.05M	34.14M	0.00	0.00
Gross Profit	-129.20M	47.16M	118.29M	-74.03M	-50.02M	-100.23M	-107.03M	-118.48M	-56.83M	12.40M	-25.38M	-31.48M	507.00K	1.24M
Gross Profit Ratio	-141.40%	87.49%	58.98%	-8,678.90%	-6,145.21%	-10,495.08%	-388.92%	-11,230.24%	-3,536.53%	24.39%	-3,753.85%	-1,184.39%	100.00%	100.00%
Research & Development	220.57M	135.56M	82.28M	74.88M	50.84M	101.18M	134.55M	119.53M	58.44M	38.45M	26.05M	34.14M	24.17M	9.79M
General & Administrative	61.84M	49.90M	46.32M	38.70M	35.74M	42.48M	48.23M	41.06M	23.11M	19.05M	15.05M	9.93M	5.58M	3.62M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	61.84M	49.90M	46.32M	38.70M	35.74M	42.48M	48.23M	41.06M	23.11M	19.05M	15.05M	9.93M	5.58M	3.62M
Other Expenses	0.00	5.95M	-54.00K	1.31M	8.40M	2.74M	-2.35M	571.00K	26.00K	310.00K	-225.00K	0.00	0.00	0.00
Operating Expenses	282.41M	185.46M	128.60M	113.59M	86.57M	143.67M	182.77M	160.59M	81.54M	57.50M	41.10M	44.07M	29.75M	13.41M
Cost & Expenses	282.41M	185.46M	128.60M	113.59M	86.57M	143.67M	182.77M	160.59M	81.54M	57.50M	41.10M	44.07M	29.75M	13.41M
Interest Income	31.01M	6.35M	42.00K	1.37M	8.20M	6.39M	3.55M	0.00	196.00K	79.00K	71.00K	5.00K	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	8.20M	3.70M	3.69M	0.00	0.00	0.00	154.00K	0.00	0.00	0.00
Depreciation & Amortization	928.00K	6.74M	6.80M	6.98M	6.82M	3.22M	3.07M	2.43M	806.00K	743.00K	660.00K	468.00K	391.00K	191.00K
EBITDA	-190.11M	-131.56M	71.98M	-111.22M	-78.94M	-152.90M	-152.19M	-156.54M	-79.13M	-5.91M	-39.77M	-40.94M	-28.85M	-11.97M
EBITDA Ratio	-208.06%	-244.05%	35.88%	-13,216.18%	-10,542.87%	-13,252.88%	-564.17%	-15,121.80%	-4,974.30%	-13.07%	-5,980.33%	-1,557.94%	-5,690.93%	-963.07%
Operating Income	-191.04M	-131.56M	71.98M	-112.73M	-85.70M	-158.86M	-155.25M	-159.54M	-79.94M	-6.65M	-40.43M	-41.41M	-29.24M	-12.16M
Operating Income Ratio	-209.08%	-244.05%	35.88%	-13,216.18%	-10,527.89%	-16,634.03%	-564.17%	-15,121.80%	-4,974.30%	-13.07%	-5,980.33%	-1,557.94%	-5,768.05%	-978.44%
Total Other Income/Expenses	30.56M	5.95M	-54.00K	1.31M	8.40M	2.74M	-2.35M	571.00K	26.00K	310.00K	-154.00K	5.00K	0.00	0.00
Income Before Tax	-160.48M	-125.61M	71.92M	-111.43M	-77.30M	-156.12M	-157.60M	-158.96M	-79.91M	-6.34M	-40.58M	-41.41M	-29.24M	-12.16M
Income Before Tax Ratio	-175.64%	-233.01%	35.86%	-13,062.95%	-9,496.07%	-16,347.12%	-572.71%	-15,067.68%	-4,972.68%	-12.47%	-6,003.11%	-1,557.75%	-5,768.05%	-978.44%
Income Tax Expense	-13.45M	-8.66M	4.95M	-283.00K	379.00K	-470.00K	-4.37M	1.14M	701.00K	811.00K	415.00K	6.00K	426.00K	320.00K
Net Income	-147.03M	-116.95M	66.98M	-111.14M	-77.68M	-155.65M	-153.24M	-160.11M	-80.61M	-7.15M	-41.00M	-41.41M	-29.67M	-12.48M
Net Income Ratio	-160.91%	-216.95%	33.39%	-13,029.78%	-9,542.63%	-16,297.91%	-556.84%	-15,176.11%	-5,016.30%	-14.06%	-6,064.50%	-1,557.98%	-5,852.07%	-1,004.18%
EPS	-2.76	-2.47	1.51	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-1.68	-0.71
EPS Diluted	-2.76	-2.47	1.38	-2.78	-1.95	-3.93	-4.07	-4.66	-2.66	-0.29	-2.20	-2.84	-1.68	-0.71
Weighted Avg Shares Out	53.22M	47.37M	44.23M	39.92M	39.88M	39.56M	37.65M	34.35M	30.33M	24.67M	18.62M	14.59M	17.68M	17.68M
Weighted Avg Shares Out (Dil)	53.22M	47.37M	48.46M	39.92M	39.88M	39.56M	37.65M	34.35M	30.33M	24.67M	18.62M	14.59M	17.68M	17.68M

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others

November 14, 2022investors.com

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled. The post Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others appeared first on...

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

November 4, 2022zacks.com

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

November 3, 2022businesswire.com

DUBLIN--(BUSINESS WIRE)---- $PRTA #ASH22--Prothena Corporation plc today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at ASH 2022.

Trading Ideas On The Upcoming CTAD 2022 Conference

November 2, 2022seekingalpha.com

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Prothena to Report Third Quarter 2022 Financial Results on November 3rd

October 27, 2022globenewswire.com

DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first...

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

September 29, 2022zacks.com

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

Why Is Prothena (PRTA) Stock Up 75% Today?

September 28, 2022investorplace.com

Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news from Biogen (NASDAQ: BIIB ) that explains why shares of PRTA...